To achieve an affordable price for its advanced cancer test, Delphi prioritizes algorithmic complexity over "wet lab" complexity. This strategy keeps physical sample processing simple and low-cost, putting the innovation into scalable software (AI/ML) to analyze the data, which is key for mass adoption.

The US healthcare system rewards inefficiency, with multiple parties adding costs. Cash-pay systems bypass this, offering services and drugs at a lower net price by avoiding negotiations and markups inherent in the insurance-based model.

Judi Health couldn't match the purchasing power of its giant competitors. Instead of competing on gross cost, they focused on being 70% more operationally efficient. This allowed them to offer a lower *net* cost to customers, proving that startups can win on price by focusing on superior internal operations, not just scale.

In the biosimilars industry, where prices inevitably decline over time, full vertical integration (from R&D to commercialization) is essential for survival. By controlling the entire value chain, companies like Biocon avoid profit-sharing with partners, preserving margins and enabling them to withstand market pressures that would cripple less integrated competitors.

Neko Health's success stems from applying hospitality principles to healthcare. By offering price transparency, respecting patient time, and providing a spa-like experience with premium amenities, it addresses key pain points ignored by traditional providers, creating a desirable, high-end service.

Function Health provides comprehensive lab testing with over 160 biomarkers, which would typically cost $15,000, for a $365 annual membership. This business model makes high-end, data-driven preventative care accessible to a much broader audience beyond the wealthy who can afford traditional concierge doctors.

By verticalizing infrastructure to offer at-home diagnostic testing for free or at cost, a healthcare company can build the world's largest health dataset. This loss leader provides immense value to patients, builds trust, and creates a powerful and defensible customer acquisition channel for high-margin treatments.

Neko’s massive waitlist demonstrates huge consumer appetite for alternatives to “Big Healthcare.” This validates the VC thesis of targeting old, slow, and disruptable monoliths. These “big blanks” are ripe for innovation, offering outsized rewards for startups that can successfully challenge them.

The current healthcare model is backwards. It's more cost-effective to proactively get comprehensive diagnostics like blood work done twice a year than to rely on multiple, expensive doctor visits after symptoms appear. This preventative approach catches diseases earlier and reduces overall system costs.